Autophagy: A potential target for thyroid cancer therapy (Review)

Yi,Heqing; Long,Bin; Ye,Xuemei; Zhang,Lijun; Liu,Xiaodong; Zhang,Chunyan

doi:10.3892/mco.2014.305

Autophagy: A potential target for thyroid cancer therapy (Review)

Authors:
- Heqing Yi
- Bin Long
- Xuemei Ye
- Lijun Zhang
- Xiaodong Liu
- Chunyan Zhang
View Affiliations

Affiliations: Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Key Laboratory of Radiobiology (Ministry of Health), School of Public Health, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: June 6, 2014 https://doi.org/10.3892/mco.2014.305
Pages: 661-665

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The sharply increasing incidence of thyroid cancer has attracted considerable attention over the last few years. The combination of surgery, radioiodine ablation and thyroid‑stimulating hormone suppression is usually efficient for the majority of thyroid tumors. However, advanced thyroid cancer that is recurrent, metastatic and 131I-refractory, or medullary thyroid cancer, pose a therapeutic challenge. Autophagy is a process that metabolizes damaged cytoplasmic organelles and long-lived proteins in order to recycle cellular materials and maintain homeostasis. It has been confirmed that autophagy plays a dual role during cancer development, progression and treatment, mainly depending on the type and stage of the tumor. Autophagy modulation has become a potential therapeutic target for diverse diseases. The mechanism of thyroid tumorigenesis and cancer progression was largely demonstrated to be correlated with the dysregulation of the Ras/Raf/mitogen-activated protein kinase kinase̸extracellular signal‑regulated kinase and the phosphoinositide 3-kinase̸Akt̸mammalian target of rapamycin pathways, as well as with abnormal epigenetic modifications. Those mechanisms are associated with autophagy regulation and may be beneficial for the treatment of advanced thyroid cancer. However, the number of available studies on the role of autophagy in thyroid cancer development, progression and treatment outcome, is currently limited. The aim of this review was to elaborate on the relevant knowledge and future prospectives of autophagy in the treatment of thyroid cancer.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER Cancer Statistics (Review), 1975–2010. National Cancer Institute; Bethesda, MD: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted on the SEER website. April. 2013
2	Lee J, Hwang JA and Lee EK: Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform. 11:68–75. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hundahl SA, Fleming ID, Fremgen AM and Menck HR: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 83:2638–2648. 1998.PubMed/NCBI
4	Smallridge RC and Copland JA: Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 22:486–497. 2010. View Article : Google Scholar : PubMed/NCBI
5	Pacini F, Castagna MG, Cipri C and Schlumberger M: Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 22:475–485. 2010. View Article : Google Scholar
6	Ball DW, Jin N, Rosen DM, et al: Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab. 92:4712–4718. 2007. View Article : Google Scholar : PubMed/NCBI
7	Roman S, Lin R and Sosa JA: Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 107:2134–2142. 2006. View Article : Google Scholar : PubMed/NCBI
8	Busaidy NL and Cabanillas ME: Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. Feb 28–2012.(Epub ahead of print).
9	Pfister DG and Fagin JA: Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 26:4701–4704. 2008. View Article : Google Scholar : PubMed/NCBI
10	Hou P, Liu D, Shan Y, et al: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 13:1161–1170. 2007. View Article : Google Scholar
11	Liebner DA and Shah MH: Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab. 2:173–195. 2011. View Article : Google Scholar : PubMed/NCBI
12	Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
13	Pacini F, Ito Y, Luster M, Pitoia F, Robinson B and Wirth L: Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 7:541–554. 2012. View Article : Google Scholar
14	Klein M, Picard E, Vignaud JM, et al: Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol. 161:41–49. 1999. View Article : Google Scholar : PubMed/NCBI
15	Santoro M, Chiappetta G, Cerrato A, et al: Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 12:1821–1826. 1996.PubMed/NCBI
16	Portella G, Vitagliano D, Borselli C, et al: Human N-ras, TRK-T1, and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, differently affect the expression of differentiation markers and the proliferation of thyroid epithelial cells. Oncol Res. 11:421–427. 1999.
17	Salvatore G, De Falco V, Salerno P, et al: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res. 12:1623–1629. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wu G, Mambo E, Guo Z, et al: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 90:4688–4693. 2005. View Article : Google Scholar
19	Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al: PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 16:17–23. 2006.PubMed/NCBI
20	Xie Z and Klionsky DJ: Autophagosome formation: core machinery and adaptations. Nat Cell Biol. 9:1102–1109. 2007. View Article : Google Scholar : PubMed/NCBI
21	Rubinsztein DC, Codogno P and Levine B: Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 11:709–730. 2012. View Article : Google Scholar : PubMed/NCBI
22	Yang ZJ, Chee CE, Huang S and Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kenific CM, Thorburn A and Debnath J: Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol. 22:241–245. 2010. View Article : Google Scholar : PubMed/NCBI
24	Eskelinen EL: The dual role of autophagy in cancer. Curr Opin Pharmacol. 11:294–300. 2011. View Article : Google Scholar : PubMed/NCBI
25	White E, Karp C, Strohecker AM, Guo Y and Mathew R: Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol. 22:212–217. 2010. View Article : Google Scholar : PubMed/NCBI
26	Qu X, Yu J, Bhagat G, et al: Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
27	Mathew R, Karp CM, Beaudoin B, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
28	Duran A, Linares JF, Galvez AS, et al: The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell. 13:343–354. 2008. View Article : Google Scholar : PubMed/NCBI
29	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lv Q, Wang W, Xue J, et al: DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res. 72:3238–3250. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gewirtz DA, Hilliker ML and Wilson EN: Promotion of autophagy as a mechanism for radiation sensitization of breast tumor cells. Radiother Oncol. 92:323–328. 2009. View Article : Google Scholar : PubMed/NCBI
32	Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G and Rodemann HP: Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol. 99:287–292. 2011. View Article : Google Scholar : PubMed/NCBI
33	He WS, Dai XF, Jin M, Liu CW and Rent JH: Hypoxia-induced autophagy confers resistance of breast cancer cells to ionizing radiation. Oncol Res. 20:251–258. 2012. View Article : Google Scholar : PubMed/NCBI
34	Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway: progress pitfalls, and promises. Curr Opin Pharmacol. 8:393–412. 2008. View Article : Google Scholar : PubMed/NCBI
35	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
36	Li H, Jin X, Zhang Z, Xing Y and Kong X: Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells. Cell Biochem Funct. 31:427–433. 2013. View Article : Google Scholar : PubMed/NCBI
37	Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
38	Fan QW, Cheng C, Hackett C, et al: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal. 3:ra812010.PubMed/NCBI
39	Furuta S, Hidaka E, Ogata A, Yokota S and Kamata T: Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene. 23:3898–3904. 2004. View Article : Google Scholar : PubMed/NCBI
40	Ogier-Denis E, Pattingre S, El Benna J and Codogno P: Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J Biol Chem. 275:39090–39095. 2000. View Article : Google Scholar
41	Lin CI, Whang EE, Abramson MA, et al: Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery. 146:1208–1214. 2009. View Article : Google Scholar : PubMed/NCBI
42	Lin CI, Whang EE, Donner DB, et al: Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 8:1217–1226. 2010. View Article : Google Scholar : PubMed/NCBI
43	Jin SM, Jang HW, Sohn SY, et al: Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells. Endocrine. 45:256–262. 2014. View Article : Google Scholar
44	Lu CH, Liu YW, Hua SC, Yu HI, Chang YP and Lee YR: Autophagy induction of reversine on human follicular thyroid cancer cells. Biomed Pharmacother. 66:642–647. 2012. View Article : Google Scholar : PubMed/NCBI
45	Lin CI, Whang EE, Lorch JH and Ruan DT: Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery. 152:1142–1149. 2012. View Article : Google Scholar : PubMed/NCBI
46	Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY and Brent GA: Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol. 199:243–252. 2008. View Article : Google Scholar
47	de Souza EC, Padrón AS, Braga WM, et al: MTOR downregulates iodide uptake in thyrocytes. J Endocrinol. 206:113–120. 2010.PubMed/NCBI
48	Ho AL, Grewal RK, Leboeuf R, et al: Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 368:623–632. 2013. View Article : Google Scholar : PubMed/NCBI
49	Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology. 148:948–953. 2007. View Article : Google Scholar : PubMed/NCBI
50	Furuya F, Shimura H, Suzuki H, et al: Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology. 145:2865–2875. 2004. View Article : Google Scholar
51	Yamamoto S, Tanaka K, Sakimura R, et al: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 28:1585–1591. 2008.PubMed/NCBI
52	Ellis L, Bots M, Lindemann RK, et al: The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 114:380–393. 2009. View Article : Google Scholar
53	Marini F, Luzi E and Brandi ML: MicroRNA role in thyroid cancer development. J Thyroid Res. May 10–2011.(Epub ahead of print). View Article : Google Scholar
54	Yu S, Liu Y, Wang J, et al: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI
55	de la Chapelle A and Jazdzewski K: MicroRNAs in thyroid cancer. J Clin Endocrinol Metab. 96:3326–3336. 2011.
56	Gambari R, Fabbri E, Borgatti M, et al: Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem Pharmacol. 82:1416–1429. 2011. View Article : Google Scholar : PubMed/NCBI
57	Janku F, McConkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 8:528–539. 2011. View Article : Google Scholar : PubMed/NCBI
58	Marotta V, Ramundo V, Camera L, et al: Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf). 78:760–767. 2013. View Article : Google Scholar